Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3720 in metastatic castration-resistant prostate cancer
NCT04853498Phase 1Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tqb3720 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Maximum tolerated dose. Started Jun 2021; status: terminated.
02
Drugs
tqb3720
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04853498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853498.